What is Coremap?
Coremap operates at the intersection of biomedical engineering and clinical cardiology, focusing on the diagnosis and treatment of atrial fibrillation (AF). The company provides advanced visualization tools that allow physicians to map irregular heart rhythms with unprecedented precision. By improving the diagnostic accuracy of AF, Coremap enables more effective intervention strategies, potentially reducing the long-term health complications associated with the condition. The firm's market position is bolstered by a multidisciplinary team of medical experts and engineers dedicated to refining the standard of care for cardiac patients globally. As the prevalence of AF continues to rise, Coremap's technological solutions represent a critical advancement in the management of chronic heart conditions, positioning the company as a key player in the digital health and medical device landscape.
How much funding has Coremap raised?
Coremap has raised a total of $69M across 3 funding rounds:
Series A
$10.5M
Series B
$23M
Stock/Share Issuance
$35.5M
Series A (2020): $10.5M with participation from Qure Ventures and Ronny Ginor
Series B (2022): $23M led by Qure Ventures and Russ Scully
Stock/Share Issuance (2026): $35.5M, investors not publicly disclosed
Key Investors in Coremap
Qure Ventures
Qure Ventures is Israel's first exclusively focused digital health fund, investing in startups within the country's leading tech and digital health ecosystem. The company aims to revolutionize medicine through digital health solutions, addressing the growing healthcare demands of an aging global population.
Ronny Ginor
Undisclosed investor participating in the funding round.
Russ Scully
Undisclosed investor participating in the funding round.
What's next for Coremap?
With the successful completion of this major enterprise-level funding, Coremap is expected to prioritize the scaling of its clinical operations and the commercialization of its core diagnostic technologies. The strategic roadmap likely includes expanding clinical trial capacity and deepening partnerships with healthcare providers to integrate its mapping solutions into standard hospital workflows. Furthermore, the company will likely focus on regulatory milestones and the refinement of its data-driven insights to enhance patient outcomes. As Coremap transitions into this next phase of growth, the focus will remain on maintaining its competitive edge through continuous innovation in cardiac electrophysiology, ensuring that its diagnostic tools remain at the forefront of the medical technology industry.
See full Coremap company page
